Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?

doi:10.1111/bjh.18915

. 2023 Aug;202(4):725-727.

doi: 10.1111/bjh.18915. Epub 2023 Jun 8.

Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?

Paul Coppo^{1

2

3}, Bérangère S Joly^{2

4

5}; French Reference Center for Thrombotic Microangiopathies (CNR-MAT)

Affiliations

¹ Service d'hématologie, AP-HP. 6 and Sorbonne - Université, Paris, France.
² Centre National de Référence des Microangiopathies thrombotiques (CNR-MAT), AP-HP. 6 and Sorbonne - Université, Paris, France.
³ Centre de Recherche des Cordeliers, INSERM UMRS1138, Paris, France.
⁴ Service d'Hématologie Biologique, Hôpital Lariboisière, AP-HP.Nord, Université Paris Cité, Paris, France.
⁵ EA3518, Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France.

PMID: 37291806
DOI: 10.1111/bjh.18915

Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?

Paul Coppo et al. Br J Haematol. 2023 Aug.

. 2023 Aug;202(4):725-727.

doi: 10.1111/bjh.18915. Epub 2023 Jun 8.

Authors

Paul Coppo^{1

2

3}, Bérangère S Joly^{2

4

5}; French Reference Center for Thrombotic Microangiopathies (CNR-MAT)

Affiliations

¹ Service d'hématologie, AP-HP. 6 and Sorbonne - Université, Paris, France.
² Centre National de Référence des Microangiopathies thrombotiques (CNR-MAT), AP-HP. 6 and Sorbonne - Université, Paris, France.
³ Centre de Recherche des Cordeliers, INSERM UMRS1138, Paris, France.
⁴ Service d'Hématologie Biologique, Hôpital Lariboisière, AP-HP.Nord, Université Paris Cité, Paris, France.
⁵ EA3518, Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France.

PMID: 37291806
DOI: 10.1111/bjh.18915

Abstract

Therapeutic options in immune-mediated thrombotic thrombocytopenic purpura (iTTP) during pregnancy are limited besides therapeutic plasma exchange (TPE) and corticosteroids. The report by Odetola et al. suggests that caplacizumab represents a reasonable option in iTTP during pregnancy, especially when the disease is not rapidly controlled with the standard TPE-corticosteroid association. Commentary on: Odetola et al. Safe and effective use of caplacizumab in pregnancy-related acquired thrombotic thrombocytopenic purpura. Br J Haematol 2023;202:879-882.

Keywords: ADAMTS13; caplacizumab; pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura; therapeutic plasma exchange.

PubMed Disclaimer

Cited by

Management and follow-up of pregnancy-onset thrombotic thrombocytopenic purpura: the French experience.
Béranger N, Coppo P, Tsatsaris V, Boisseau P, Provôt F, Delmas Y, Poullin P, Vanhoorelbeke K, Veyradier A, Joly BS. Béranger N, et al. Blood Adv. 2024 Jan 9;8(1):183-193. doi: 10.1182/bloodadvances.2023011972. Blood Adv. 2024. PMID: 38039511 Free PMC article.
Methods for Engineering Binders to Multi-Pass Membrane Proteins.
Thomas B, Chockalingam K, Chen Z. Thomas B, et al. Bioengineering (Basel). 2023 Nov 24;10(12):1351. doi: 10.3390/bioengineering10121351. Bioengineering (Basel). 2023. PMID: 38135942 Free PMC article. Review.
Genetic association of preeclampsia to von Willebrand factor and its size-regulator ADAMTS13.
Lokki AI, Triebwasser M, Daly E, Kurki MI, Perola M, Auro K, Java A, Salmon JE, Heinonen S, Kajantie E, Kere J, Lassila R, Daly M, Atkinson JP, Laivuori H, Meri S. Lokki AI, et al. Res Sq [Preprint]. 2025 Jul 8:rs.3.rs-5685318. doi: 10.21203/rs.3.rs-5685318/v1. Res Sq. 2025. PMID: 40671815 Free PMC article. Preprint.
Novel mechanisms of action of emerging therapies of hereditary thrombotic thrombocytopenic purpura.
Zheng XL. Zheng XL. Expert Rev Hematol. 2024 Jul;17(7):341-351. doi: 10.1080/17474086.2024.2356763. Epub 2024 May 20. Expert Rev Hematol. 2024. PMID: 38752747 Free PMC article. Review.

References

REFERENCES

1. Odetola O, Martin KA, Dreyer M, Rajan P, Zakarija A, Stein BL. Safe and effective use of caplacizumab in pregnancy-related acquired thrombotic thrombocytopenic purpura. Br J Haematol. 2023;202:879-82.
1. Scully M, Thomas M, Underwood M, Watson H, Langley K, Camilleri RS, et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood. 2014;124(2):211-9.
1. Coppo P, Veyradier A, French Reference Center for Thrombotic Microangiopathies (CNR-MAT). TTP in the setting of pregnancy: the story still has to be written. J Thromb Haemost. 2020;18(10):2775-7.
1. Ferrari B, Peyvandi F. How I treat thrombotic thrombocytopenic purpura in pregnancy. Blood. 2020;136(19):2125-32.
1. Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335-46.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley

[1] Odetola O, Martin KA, Dreyer M, Rajan P, Zakarija A, Stein BL. Safe and effective use of caplacizumab in pregnancy-related acquired thrombotic thrombocytopenic purpura. Br J Haematol. 2023;202:879-82.

[2] Odetola O, Martin KA, Dreyer M, Rajan P, Zakarija A, Stein BL. Safe and effective use of caplacizumab in pregnancy-related acquired thrombotic thrombocytopenic purpura. Br J Haematol. 2023;202:879-82.

[3] Scully M, Thomas M, Underwood M, Watson H, Langley K, Camilleri RS, et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood. 2014;124(2):211-9.

[4] Scully M, Thomas M, Underwood M, Watson H, Langley K, Camilleri RS, et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood. 2014;124(2):211-9.

[5] Coppo P, Veyradier A, French Reference Center for Thrombotic Microangiopathies (CNR-MAT). TTP in the setting of pregnancy: the story still has to be written. J Thromb Haemost. 2020;18(10):2775-7.

[6] Coppo P, Veyradier A, French Reference Center for Thrombotic Microangiopathies (CNR-MAT). TTP in the setting of pregnancy: the story still has to be written. J Thromb Haemost. 2020;18(10):2775-7.

[7] Ferrari B, Peyvandi F. How I treat thrombotic thrombocytopenic purpura in pregnancy. Blood. 2020;136(19):2125-32.

[8] Ferrari B, Peyvandi F. How I treat thrombotic thrombocytopenic purpura in pregnancy. Blood. 2020;136(19):2125-32.

[9] Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335-46.

[10] Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335-46.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?

Affiliations

Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?

Authors

Affiliations

Abstract

Similar articles

Cited by

References

REFERENCES

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Abstract

Similar articles

Cited by

References

REFERENCES

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources